Echtzeit-Aktienkurs Progenics Pharmaceuticals
Bid:
Ask:
Echtzeit-Chart der Progenics Pharmaceuticals Aktie
Fundamentaldaten der Progenics Pharmaceuticals Aktie
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2019 [USD] | 34,99 Mio. | -68,54 Mio. | -68,55 Mio. | -0,80 | - | - | - |
| 2018 [USD] | 15,62 Mio. | -69,29 Mio. | -67,66 Mio. | -0,87 | - | - | - |
| 2017 [USD] | 11,70 Mio. | -62,69 Mio. | -51,01 Mio. | -0,73 | - | - | - |
| 2016 [USD] | 69,43 Mio. | 12,58 Mio. | 10,81 Mio. | 0,15 | - | - | - |
| 2015 [USD] | 8,68 Mio. | -39,25 Mio. | -39,11 Mio. | -0,56 | - | - | - |
| 2014 [USD] | 44,38 Mio. | 3,42 Mio. | 4,41 Mio. | 0,06 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der Progenics Pharmaceuticals Aktie
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.